NDAINTRAVITREALIMPLANTPriority Review
Approved
Apr 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
18
Data completeness
3/8 — Basic
Priority Review
RETISERT (fluocinolone acetonide) by Bausch + Lomb is corticosteroid hormone receptor agonists [moa]. First approved in 2005.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RETISERT is an intravitreal implant delivering fluocinolone acetonide, a corticosteroid that works as a hormone receptor agonist to suppress inflammation. It is indicated for chronic non-infectious uveitis affecting the posterior segment of the eye. The implant provides sustained local drug delivery over an extended period.
LOE Approaching
With LOE approaching and low competitive pressure (30%), the brand faces heightened urgency around lifecycle extension; team sizes will likely contract as revenue declines.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (18)
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Started Nov 2023
600 enrolled
Radiation RetinopathyVisual Impairment
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
Started Jun 2022
125 enrolled
Uveitis, Posterior
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
Started Jul 2017
3 enrolled
Uveitis, Posterior
Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant
Started Feb 2016
98 enrolled
InflammationUveitis
Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study
Started Apr 2011
120 enrolled
Diabetic Macular Edema
Worked on RETISERT at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.